URINARY MARKERS TO INDEX SKELETAL GROWTH

反映骨骼生长的尿液标志物

• 批准号: 2131037
• 负责人: ANNE-MARIE BOLLEN
• 金额: $ 9.73万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2131037
• 关键词: adolescence (12-20); age difference; biomarker; body height; bone development; bone metabolism; chromatography; collagen; creatinine; facial bones; gender difference; human subject; human therapy evaluation; immunologic assay /test; longitudinal human study; lysine; mandible /maxilla; orthodontics; urinalysis

In orthodontics, timing of growth modification in adolescents is an important determinant of treatment success. Treatment results depend on the rates of bone growth which vary during different stages of maturation. However, currently no reliable markers exist for measuring changes in bone growth stages. The purpose of this study is to explore the use of specific urinary metabolites of bone collagen as markers for timing of orthodontic treatment. The specific aims are 1) to correlate urinary hydroxylysyl-pyridinoline (HP) and lysyl-pyridinoline (LP) excretion with facial bone growth velocity, 2) to provide a diagnostic decision rule to determine an individual's adolescent maturational stage, and 3) to evaluate the outcome of facial orthopaedic treatment as a function of the HP and LP excretion at the start of treatment. A prospective cohort study is designed in which urine samples, facial and statural growth measurements are gathered from adolescents on a monthly basis. From these data, the correlation between facial growth velocity and urinary HP/creatinine and LP/creatinine excretion ratios will be investigated using generalized estimating equations. Different adolescent maturational stages will be derived from the statural height growth velocity curves which will be smoothed using a cubic spline method. A diagnostic decision rule will be constructed using logistic discriminant analysis to classify individuals in maturational stages using HP and LP excretion, age and sex. A subgroup of the cohort will be comprised of patients that are treated with mandibular orthopaedic appliance. The results of treatment will be evaluated as a function of the quantity of urinary excretion of HP and LP at the start of treatment. The potential clinical implication is that the proposed urinary markers would allow orthodontists to time growth intervention to obtain optimum treatment results.

在正畸学中，青少年生长改变的时机是一个关键因素 治疗成功的重要决定因素。 治疗结果取决于 不同阶段的骨骼生长速度不同 成熟。 然而，目前还没有可靠的标记物来测量 骨骼生长阶段的变化。 本研究的目的是探索 使用骨胶原的特定尿代谢物作为标记物 正畸治疗的时机。 具体目标是 1) 关联 尿羟赖氨酰吡啶啉 (HP) 和赖氨酰吡啶啉 (LP) 随面部骨骼生长速度的排泄，2) 提供诊断 决定个体青春期成熟阶段的决策规则， 3) 评估面部整形外科治疗的结果 治疗开始时 HP 和 LP 排泄的功能。 设计了一项前瞻性队列研究，其中尿液样本、面部和 每月收集青少年的身高生长测量值 基础。 根据这些数据，面部生长速度之间的相关性 尿 HP/肌酐和 LP/肌酐排泄率将为 使用广义估计方程进行研究。 不同的 青少年的成熟阶段将从身高得出 将使用三次样条平滑的生长速度曲线 方法。 将使用逻辑构建诊断决策规则 判别分析对成熟阶段的个体进行分类 使用 HP 和 LP 排泄、年龄和性别。 该队列的一个亚组将由接受治疗的患者组成 带有下颌骨矫形器。 治疗结果将是 评估为 HP 和尿排泄量的函数 治疗开始时的 LP。 潜在的临床意义是所提出的尿液标记物 允许正牙医生及时进行生长干预以获得最佳效果 治疗结果。